Walder Wyss’ IP team successfully represented the pharmaceutical company Merck in appeal proceedings before the Swiss Federal Supreme Court against its US competitor MSD. The case Following World War I, Merck’s US subsidiary, which
Tags :Walder Wyss
The team was led by partner Florian Gunz Niedermann (Corporate/ M&A - pictured) and also included associate Sebastian Wyler (Corporate / M&A).
Walder Wyss acted as Swiss counsel to CRISPR in connection with the transaction. The team was led by partner Alex Nikitine. Homburger acted as legal counsel to Goldman Sachs & Co. LLC, BofA Securities, Inc. and
Walder Wyss advised Crédit Mutuel Equity in relation to this investment. The team was led by partner Luc Defferrard (M&A)
Walder Wyss advised Pexapark in this transaction. The team included partners Ramona Wyss (Energy/M&A), Florian Gunz (M&A) and associate Timon Nydegger (M&A).
After receipt of the required regulatory permits and completion of the agreed carve-out the transaction was closed on 8 June 2020. Walder Wyss acted as lead counsel to the private sellers
Filtration Group (Chicago), an affiliate of Madison Industries, acquired Switzerland based Oxyphen, an innovator in track-etched membranes.
University Hospital Zurich retained Walder Wyss to conduct an investigation into the department of cardiac surgery, in particular regarding alleged conflicts of interests of the head of the department in relation to the use of
Medbase, part of the group of Migros, and the owners of zahnarztzenturm.ch signed an agreement to acquire the majority of the shares
BioMarin Pharmaceutical announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR, a gene therapy platform company,
